Medullary Thyroid Carcinoma and Associated Multiple Endocrine Neoplasia Type 2

Clinical Endocrine Oncology: Second Edition

Volumn , Issue , 2009, Pages 515-522

  Grant, Clive S ^a  

^a MAYO CLINIC   (United States)

Author keywords

External beam radiation; chemotherapy; Familial medullary thyroid carcinoma; MEN 2A; MEN 2B; Multiple endocrine neoplasia 2A; Multiple endocrine neoplasia 2B; Sporadic or hereditary MTC with elevated calcitonin level; Total thyroidectomy

Indexed keywords

EID: 70349877791     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300222.ch69     Document Type: Chapter

References (21)

1. Hazard J, Hawk W, Crile GJ. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J. Clin. Endocrinol. Metab. 1959; 19:152-161.
2. Gagel R. Molecular abnormalities in thyroid carcinoma. In Thyroid Cancer and Hyperparathyroidism. Boston, MA: 2001.
3. Gagel R. Putting the bits and pieces of the RET proto-oncogene puzzle together. Bone 1995;17:13S-16S.
4. Wells SJ, Chi D, Toshima K. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994; 220:237-247.
5. Wells SJ, Franz C. Medullary carcinoma of the thyroid gland. World J. Surg. 2000; 24:952-956.
6. Brandi M, Gagel R, Angeli A, et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 2001; 86:5658-5671.
7. Yip L, Cote G, Shapiro S, et al. Multiple Endocrine Neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch. Surg. 2003; 138:409-416.
8. Yip L, Lee J, Shapiro S, et al. Surgical management of hereditary pheochromocytoma. J. Am. Coll. Surg. 2004; 198:525-535.
9. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab. 2001;86:1104-1109
10. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 1990; 212:395-401.
11. Tisell L-E, Hansson G, Hansson S. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986; 99:60-66.
12. Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann. Surg. 1997; 225:734-743.
13. Kebebew E, Kikuchi S, Duh Q-Y, Clark O. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch. Surg. 2000; 135:895-901.
14. Wells S, You Y, Lakhani V, et al. The use of ZACTIMA(TM) (ZD6474) in the treatment of patients with hereditary medullary thyroid carcinoma: AACR-NCI-EORTC; 2005. Report No.: B248.
15. Strock C, Park J-I, Rosen D, et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2006; 91:79-84.
16. Sipple J. The association of pheochromocytoma with carcinoma of the thyroid gland. Am. J. Med. 1961; 31:163-166.
17. Copp D, Cameron E, Cheney B. Evidence for calcitonin-a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 70:638-649.
18. Schimke R, Hartmann W, Prout T, Rimoin D. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of chromaffin tissue. N. Engl. J. Med. 1968; 279:1-7.
19. Mulligan L, Kwok J, Healey C, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363:458-460.
20. Donis-Keller H, Dou S, Chi D, et al. Mutations in the ret protooncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993; 7:851-856.
21. Santoro M, Carlogmagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 1995; 267:381-383.